Bioinformatics Market Size, Share, Opportunities, And Trends By Application (Drug Discovery, Personal and Preventive Medicine, Crop Improvement and Insect Resistance, Others), By Biological Data (DNA, RNA, Protein, Gene Expression Profiles, Chromosomal Mapping, Others), And By Geography - Forecasts From 2025 To 2030

Comprehensive analysis of demand drivers, supply-side constraints, competitive landscape, and growth opportunities across applications and regions.

Report CodeKSI061610545
PublishedJul, 2025

Description

Bioinformatics Market Size:

The Bioinformatics Market is expected to grow from USD 15.134 billion in 2025 to USD 30.361 billion in 2030, at a CAGR of 14.94%.

Bioinformatics is the use of computational and analytical tools to gather and analyze biological data. The use of computer programs to discover gene and protein functions, establish evolutionary connections, and forecast the three-dimensional structures of proteins is known as bioinformatics.

Bioinformatics is becoming crucial since massive volumes of data generated by techniques such as protein and nucleic acid sequencing necessitate data interpretation and management for medical applications and future research. As a result, growing demand is projected to propel the bioinformatics market throughout the forecast period.

However, expensive bioinformatics software and service prices, as well as a scarcity of experienced specialists, are anticipated to impede industry expansion in the coming years.

Bioinformatics Market Growth Factor:

  • Increasing bioinformatics funding from the public and private sectors.

Many governments and private companies across the globe are making substantial investments in bioinformatics to enable high-quality solutions and services through data and the latest technologies. For instance, with a EUR 20 million investment, the UK government formed a new alliance named COVID-19 Genomics UK Consortium (COG-UK) in March 2020 to sequence the genomes of SARS-CoV-2 the virus that is causing the ongoing COVID-19 pandemic. The NHS, Public Health Agencies, the Wellcome Sanger Institute, and several academic institutions comprise the COVID-19 Genomics UK Consortium (COG-UK). Such factors are anticipated to drive the growth of the bioinformatics market.

Bioinformatics Market Restraints:

  • High Equipment Costs

With the introduction of sophisticated next-generation sequencing (NGS) technology, there is a growing demand for rapid and accurate bioinformatics tools that are simple to use. The majority of experimental researchers are not bioinformaticians. As a result, the availability of user-friendly tools is critical for using bioinformatics platforms. Many bioinformatics applications necessitate extensive computer skills, owing to a lack of a suitable user interface. Genomics instruments are also outfitted with advanced features and functions, and as a result, they are priced at a premium, ranging from USD 10–20 million. Since pharmaceutical companies and research institutes require a large number of such devices, the financial investment in acquiring many genomic instruments is substantial. Small and medium-sized pharmaceutical companies and research facilities cannot afford to make such large expenditures in numerous genomics equipment.

Bioinformatics Market Segmentation:

  • By Application
    • Drug Discovery and Development
    • Personalized and Preventive Medicine
    • Genomics and Genetic Research
    • Molecular Medicine
    • Clinical Diagnostics
    • Forensic and Environmental Bioinformatics
    • Others
  • By Biological Data Type
    • Genomics
    • Transcriptomics
    • Proteomics
    • Metabolomics
    • Pharmacogenomics
    • Cheminformatics
    • Epigenomics
    • Others
  • By End-User
    • Pharmaceutical and Biotechnology Companies
    • Academic and Research Institutes
    • Agricultural Research Organizations
    • Hospitals and Clinics
    • Contract Research Organizations (CROs)
    • Others
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Others
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Taiwan
      • Others

Table Of Contents

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. BIOINFORMATICS MARKET BY APPLICATION

5.1. Introduction

5.2. Drug Discovery and Development

5.3. Personalized and Preventive Medicine

5.4. Genomics and Genetic Research

5.5. Molecular Medicine

5.6. Clinical Diagnostics

5.7. Forensic and Environmental Bioinformatics

5.8. Others

6. BIOINFORMATICS MARKET BY BIOLOGICAL DATA TYPE

6.1. Introduction

6.2. Genomics

6.3. Transcriptomics

6.4. Proteomics

6.5. Metabolomics

6.6. Pharmacogenomics

6.7. Cheminformatics

6.8. Epigenomics

6.9. Others

7. BIOINFORMATICS MARKET BY END-USER

7.1. Introduction

7.2. Pharmaceutical and Biotechnology Companies

7.3. Academic and Research Institutes

7.4. Agricultural Research Organizations

7.5. Hospitals and Clinics

7.6. Contract Research Organizations (CROs)

7.7. Others

8. BIOINFORMATICS MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Application

8.2.2. By Biological Data Type

8.2.3. By End-User

8.2.4. By Country

8.2.4.1. USA

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Application

8.3.2. By Biological Data Type

8.3.3. By End-User

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Application

8.4.2. By Biological Data Type

8.4.3. By End-User

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.2. Germany

8.4.4.3. France

8.4.4.4. Spain

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Application

8.5.2. By Biological Data Type

8.5.3. By End-User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. UAE

8.5.4.3. Others

8.6. Asia Pacific

8.6.1. By Application

8.6.2. By Biological Data Type

8.6.3. By End-User

8.6.4. By Country

8.6.4.1. China

8.6.4.2. Japan

8.6.4.3. India

8.6.4.4. South Korea

8.6.4.5. Taiwan

8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Thermo Fisher Scientific Inc.

10.2. Illumina Inc.

10.3. QIAGEN N.V.

10.4. Agilent Technologies Inc.

10.5. PerkinElmer Inc.

10.6. Eurofins Scientific

10.7. DNAnexus Inc.

10.8. BGI Group

10.9. Waters Corporation

10.10. DNASTAR Inc.

11. APPENDIX

11.1. Currency

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

Companies Profiled

Thermo Fisher Scientific Inc.

Illumina Inc.

QIAGEN N.V.

Agilent Technologies Inc.

PerkinElmer Inc.

Eurofins Scientific

DNAnexus Inc.

BGI Group

Waters Corporation

DNASTAR Inc.

Related Reports